Table 1 Baseline characteristics of patients with gout or calcium pyrophosphate deposition disease in prosthetic joints
Characteristic | N (%) or Median (IQR) |
|---|---|
Age (years) | 71.0 (61.8–77.0) |
Sex | Â |
 Male | 21/44 (47.7) |
 Female | 23/44 (52.3) |
Pertinent Medical History | Â |
 Gout | 13/29 (44.8) |
 CPPD | 1/20 (5.0) |
  Rheumatological disease | 1/10 (10.0) |
  Diabetes mellitus | 11/18 (61.1) |
  Chronic kidney disease | 10/18 (55.6) |
  Hypertension | 14/19 (73.7) |
Medication use | Â |
 Allopurinol | 8/14 (18.2) |
Chief Symptoms | Â |
 Fever | 19/40 (47.5) |
 Joint pain | 41/42 (97.6) |
 Joint swelling | 37/37 (100) |
 Erythema | 17/22 (77.3) |
 Warmth of affected joints | 23/23 (100) |
 Decreased range of motion | 30/41 (73.2) |
Reason for Prosthetic Joints | Â |
 Osteoarthritis | 26/44 (59.1) |
 Unspecified | 15/44 (34.1) |
 Others | 3/44 (6.8) |
Affected Prosthetic Joints | Â |
 Knee (includes 6 cases of bilateral knee arthroplasty involvement) | 41/44 (93.2) |
 Hip | 2/44 (4.5) |
 1st MTP | 1/44 (2.3) |
Number of Affected Joints on Presentation | Â |
 Monoarticular Prosthetic Joint | 35/44 (79.5) |
 Bilateral-Contralateral Prosthetic Joints | 7/44 (15.9) |
 Polyarticular Including Native Joints | 2/44 (4.5) |